Transplantation of a Novel Recombinant Adeno-Associated Virus (pAAV-HE1B19K-TE1A) Demonstrates Higher Anti-Tumor Effects in Tumor Cells

Background Oncolytic viruses (OVs) can specifically infect and kill tumor cells. Adeno-associated virus (AAV) is a widely-studied OV. This study aimed to construct a tumor-targeted recombinant AAV using genetic engineering technology. Material/Methods The transgene plasmid pAAV-HE1B19K-TE1A was constructed with 4 genes (hTERT, E1A, HKII, and E1B19K) and co-transfected with pAAV-RC and pHelper to tumor cells (HepG2, A549, BGC-803) and normal cells (HUVEC). rAAV was verified with fluorescence microscopy. Quantitative PCR (qPCR) assay was used to test the titer of rAAV in each cell line. Apoptosis was analyzed using qPCR and Western blot assay. MTT was used to detect the effect of rAAV on cell viability. Results The pAAV-HE1B19K-TE1A transgene plasmid was successfully structured. pAAV-HE1B19K-TE1A was highly expressed in all tumor cells. The titers of pAAV-HE1B19K-TE1A in HepG2, A549, and BGC-803 were 7.4×107, 1.4×108, and 1.1×108 gc/μl, respectively. pAAV-HE1B19K-TE1A significantly decreased cell viability of tumor cells compared to that in HUVEC (p<0.05). pAAV-HE1B19K-TE1A remarkably triggered cleaved caspase 3 (C-caspase 3) activity in tumor cells compared to that in untransfected tumor cells (p<0.05). pAAV-HE1B19K-TE1A significantly induced release of cytochrome C (Cyto C) in tumor cells compared to that in untransfected tumor cells (p<0.05). pAAV-HE1B19K-TE1A demonstrated no toxicity to vital tissues of animals. Conclusions Tumor-targeted rAAV was successfully produced using the Helper-free system with recombinant plasmid, demonstrating high efficacy in decreasing viability of tumor cells without adverse effects on normal cells.

[1]  R. Samulski,et al.  Engineering adeno-associated virus vectors for gene therapy , 2020, Nature Reviews Genetics.

[2]  M. Sena-Esteves,et al.  Production of Recombinant Adeno-Associated Viruses (rAAVs) by Transient Transfection. , 2020, Cold Spring Harbor protocols.

[3]  I. Trapani.  Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina , 2019, Genes.

[4]  J. Qiu,et al.  Development of a Novel Recombinant Adeno-Associated Virus Production System Using Human Bocavirus 1 Helper Genes , 2018, Molecular therapy. Methods & clinical development.

[5]  H. Kaufman,et al.  Integrating oncolytic viruses in combination cancer immunotherapy , 2018, Nature Reviews Immunology.

[6]  S. Crosson,et al.  Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation , 2018, Molecular therapy. Methods & clinical development.

[7]  Erdahl T. Teber,et al.  Telomere sequence content can be used to determine ALT activity in tumours , 2018, Nucleic acids research.

[8]  N. Zarghami,et al.  Zinc sulfate contributes to promote telomere length extension via increasing telomerase gene expression, telomerase activity and change in the TERT gene promoter CpG island methylation status of human adipose-derived mesenchymal stem cells , 2017, PloS one.

[9]  M. S. Chapman,et al.  Adeno-associated Virus (AAV) Serotypes Have Distinctive Interactions with Domains of the Cellular AAV Receptor , 2017, Journal of Virology.

[10]  R. Moffitt,et al.  Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer , 2016, Oncotarget.

[11]  Muhammad Khairul Ramlee,et al.  Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene , 2016, Genes.

[12]  J. Lee,et al.  Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma , 2016, Oncotarget.

[13]  R. Samulski,et al.  AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. , 2014, Annual review of virology.

[14]  V. Shoshan-Barmatz,et al.  VDAC1: from structure to cancer therapy , 2012, Front. Oncol..

[15]  V. V. D. van der Velden,et al.  Human telomere disease due to disruption of the CCAAT box of the TERC promoter. , 2011, Blood.

[16]  A. Das,et al.  Effect of tacrolimus on energy metabolism in human umbilical endothelial cells. , 2011, Annals of transplantation.

[17]  D. Kirn,et al.  From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. , 2007, Current cancer drug targets.

[18]  T. Inaba,et al.  The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus vector production. , 2004, The Journal of general virology.

[19]  Y. Kondo,et al.  Telomerase as a therapeutic target for malignant gliomas , 2002, Oncogene.

[20]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[21]  R. Samulski,et al.  AAV vectors: is clinical success on the horizon? , 2000, Gene Therapy.

[22]  M. Yutsudo,et al.  Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. , 1999, Cancer research.

[23]  L. Villarreal,et al.  Adeno-associated virus vectors can be efficiently produced without helper virus , 1998, Gene Therapy.

[24]  T. Cech,et al.  Reversing Time: Origin of Telomerase , 1998, Cell.

[25]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[26]  R. Linden,et al.  Site-specific integration by adeno-associated virus: a basis for a potential gene therapy vector , 1997, Gene Therapy.

[27]  C. Greider,et al.  Telomere length regulation. , 1996, Annual review of biochemistry.

[28]  B. Leber,et al.  Telomerase activity in normal leukocytes and in hematologic malignancies. , 1995, Blood.

[29]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.